Developing new RNA-based therapies for targeted gene silencing
Creation of the Next Generation RNAi Therapeutics and an in vivo model for their study
This study is exploring new treatments that use tiny particles to target and turn off specific genes linked to adenocarcinoma, aiming to provide patients with more effective and safer options for their condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mirimus, INC. NIH-funded |
| Lab location | 1 site (Brooklyn, UNITED STATES) |
| Project ID | NIH-11007596 on NIH RePORTER |
What this research studies
This research focuses on creating next-generation RNA interference (RNAi) therapeutics that can specifically target and silence genes associated with diseases like adenocarcinoma. By utilizing advanced delivery mechanisms, such as lipid nanoparticles and viral vectors, the research aims to improve the effectiveness of these therapies while minimizing side effects. Patients may benefit from more precise treatments that can effectively address their specific genetic conditions. The research will also involve developing an in vivo model to study these therapies in a living organism.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with adenocarcinoma or other conditions that could benefit from targeted gene silencing therapies.
Not a fit: Patients with conditions unrelated to gene expression or those who do not have adenocarcinoma may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with conditions like cancer by precisely targeting disease-related genes.
How similar studies have performed: Previous research has shown promise in RNAi therapies, particularly in liver diseases, indicating potential for success in similar approaches.
Where this research is happening
Brooklyn, UNITED STATES
- Mirimus, INC. — Brooklyn, United States (Active)
Researchers
- Principal investigator: Premsrirut, Prem Khovabutr — Mirimus, INC.
- Study coordinator: Premsrirut, Prem Khovabutr
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.